Jan Birger Fredrik Toernell
Director/Board Member chez ABLIVA AB
Profil
Jan Birger Fredrik Toernell currently works at Innoex AB, as Chairman & Chief Executive Officer, Innoext AB, as Chief Executive Officer & Director from 2011, Glactone Pharma AB, as Chairman from 2012, Glactone Pharma Development AB, as Chairman, Abliva AB, as Independent Director from 2017, Diaprost AB, as Director from 2012, Stayble AB, as Director, Lidds Pharma AB, as Deputy Director, the University of Gothenburg, as Professor, Aqilion AB, as Partner from 2012, and Sahlgrenska University, as Professor.
Dr. Toernell also formerly worked at Oncorena AB, as Chief Executive Officer, Oncorena Holding AB, as Chief Executive Officer, LIDDS AB, as Independent Chairman, Isofol Medical AB, as Chairman, Stayble Therapeutics AB, as Director, Hammars Bryggeri AB, as Director, AstraZeneca PLC, as Vice President-Global Strategy, and Puls AB, as Partner.
Dr. Toernell received his doctorate degree from the University of Gothenburg.
Postes actifs de Jan Birger Fredrik Toernell
| Sociétés | Poste | Début |
|---|---|---|
| ABLIVA AB | Director/Board Member | 27/04/2017 |
| University of Gothenburg | Corporate Officer/Principal | - |
| Sahlgrenska University | Corporate Officer/Principal | - |
Innoext AB
 Innoext AB Miscellaneous Commercial ServicesCommercial Services Innoext AB provides management consulting services. The private company is based in Västra Frölunda, Sweden. Jan Birger Fredrik Toernell has been the CEO of the Swedish company since 2011. | Chief Executive Officer | 01/07/2011 |
| Lidds Pharma AB | Corporate Officer/Principal | - |
Aqilion AB
 Aqilion AB Investment ManagersFinance Aqilion AB is a venture capital firm. The firm was founded in 2002 by Jan Ekberg and Mats G. Ringesten. It's headquartered in Helsingborg, Sweden. | Private Equity Investor | 29/05/2012 |
Glactone Pharma AB
 Glactone Pharma AB Pharmaceuticals: MajorHealth Technology Glactone Pharma AB engages in the development of pipeline of novel signal transducer and activator of transcription 3 inhibitors. Its pipeline is used for immuno-oncology and for the treatment of drug resistant cancers, including castration resistant prostate cancer. The company was founded by Anders Sigvard Bjartell, Rebecka Hellsten, Martin Johansson, Eduardo Munoz, and Olov Arvid Sterner in 2012 and is headquartered in Helsingborg, Sweden. | Chairman | 01/07/2012 |
| Stayble AB | Director/Board Member | - |
Diaprost AB
 Diaprost AB Miscellaneous Commercial ServicesCommercial Services Diaprost AB is a private pharmaceutical research and development company based in Lund, Sweden. Diaprost collaborates with leading international experts in the fields of molecular medicine, biotechnology, immunology, radiology, radiation physics, laboratory medicine, and oncology. The Swedish company has an agreement with a top 10 pharma company for its first antibody H11B6 targeting the HK2 antigen, which is in early clinical development. The remaining Diaprost pipeline consists of 5A10, which targets free-PSA antigen for both diagnostic and therapeutic applications. The company was founded in 2005 with the aim of leveraging the transformative success of the PSA assay for detection of prostate cancer as a personalized theranostic platform. Johan Drott has been the CEO of the company since 2015. | Director/Board Member | 01/06/2012 |
| ░░░░░░ ░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | - |
Anciens postes connus de Jan Birger Fredrik Toernell
| Sociétés | Poste | Fin |
|---|---|---|
| ░░░░ ░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
| ░░░░░░░ ░░░░░░░░░░░░ ░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
| ░░░░░░░░ ░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | - |
| ░░░░░░░░ ░░░░░░░ ░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | - |
| ░░░░░░ ░░░░░░░ ░░ | ░░░░░░░░ | - |
Formation de Jan Birger Fredrik Toernell
| University of Gothenburg | Doctorate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 5 |
|---|---|
| ASTRAZENECA PLC | Health Technology |
| ABLIVA AB | Health Technology |
| LIDDS AB | Health Technology |
| ISOFOL MEDICAL AB | Health Technology |
| STAYBLE THERAPEUTICS AB | Health Technology |
| Entreprise privées | 12 |
|---|---|
Aqilion AB
Aqilion AB Investment ManagersFinance Aqilion AB is a venture capital firm. The firm was founded in 2002 by Jan Ekberg and Mats G. Ringesten. It's headquartered in Helsingborg, Sweden. | Finance |
Oncorena AB
 Oncorena AB Pharmaceuticals: MajorHealth Technology Oncorena AB develops a novel pharmacological treatment for metastatic renal clear cell cancer. It conducts clinical trial for potential new therapies in humans. The company was founded in 2011 and is headquartered in Helsingborg, Sweden. | Health Technology |
Glactone Pharma AB
Glactone Pharma AB Pharmaceuticals: MajorHealth Technology Glactone Pharma AB engages in the development of pipeline of novel signal transducer and activator of transcription 3 inhibitors. Its pipeline is used for immuno-oncology and for the treatment of drug resistant cancers, including castration resistant prostate cancer. The company was founded by Anders Sigvard Bjartell, Rebecka Hellsten, Martin Johansson, Eduardo Munoz, and Olov Arvid Sterner in 2012 and is headquartered in Helsingborg, Sweden. | Health Technology |
| Glactone Pharma Development AB | |
Oncorena Holding AB
 Oncorena Holding AB Pharmaceuticals: MajorHealth Technology Oncorena Holding AB develops novel pharmacological treatment for metastatic renal clear cell cancer. It conducts clinical trial for potential new therapies. The company was founded by Björn Oskar Larsson in 2011 and is headquartered in Helsingborg, Sweden. | Health Technology |
Diaprost AB
Diaprost AB Miscellaneous Commercial ServicesCommercial Services Diaprost AB is a private pharmaceutical research and development company based in Lund, Sweden. Diaprost collaborates with leading international experts in the fields of molecular medicine, biotechnology, immunology, radiology, radiation physics, laboratory medicine, and oncology. The Swedish company has an agreement with a top 10 pharma company for its first antibody H11B6 targeting the HK2 antigen, which is in early clinical development. The remaining Diaprost pipeline consists of 5A10, which targets free-PSA antigen for both diagnostic and therapeutic applications. The company was founded in 2005 with the aim of leveraging the transformative success of the PSA assay for detection of prostate cancer as a personalized theranostic platform. Johan Drott has been the CEO of the company since 2015. | Commercial Services |
| Innoex AB | |
| Stayble AB | |
Hammars Bryggeri AB
 Hammars Bryggeri AB Beverages: AlcoholicConsumer Non-Durables Hammars Bryggeri AB engages in brewery operations. It produces a wide range of soft drinks, water, and other cider beverages. The company was founded in 1904 and is headquartered in Hammar, Sweden. | Consumer Non-Durables |
Innoext AB
Innoext AB Miscellaneous Commercial ServicesCommercial Services Innoext AB provides management consulting services. The private company is based in Västra Frölunda, Sweden. Jan Birger Fredrik Toernell has been the CEO of the Swedish company since 2011. | Commercial Services |
| Lidds Pharma AB | |
Puls AB
 Puls AB Environmental ServicesIndustrial Services Puls AB is a private company based in southern Sweden that specializes in sewage, industrial, and environmental services. The Swedish company's on-call services include emergency stops in the drain, sewage cleaning, and wastewater flushing. The company also uses water blasting as an environmentally friendly method to clean tanks, cisterns, sheet metal, and boat hulls. Puls is the largest player in VA maintenance in southern Sweden and has a team of talented employees who specialize in water and wastewater in tenant-owner associations. The company offers preventive maintenance work and emergency measures to help associations with their maintenance needs. | Industrial Services |
